Can a vaccine boost TB treatment? new trial aims to find out
NCT ID NCT06205589
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental vaccine called ID93 + GLA-SE in 1500 people with drug-susceptible pulmonary TB. Participants receive the vaccine or a placebo alongside their regular TB treatment. Researchers want to see if the vaccine can improve immune responses and reduce poor outcomes like treatment failure or TB coming back. It is the first time this vaccine is tested in people living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ID93 + GLA-SE vaccine
What this could lead to
If successful, this vaccine could become an add-on to standard TB treatment, reducing treatment failure and TB recurrence.
What could go wrong
This is a Phase 2 trial, so it is still early. The vaccine may not prove effective or safe in larger populations, and results may not apply to all TB patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••